Joining Brian and myself in our studio (again, that is two in a row) we delighted to speak to Chris Scudder, Senior Lecturer in Internal Medicine and Co-Head of the Internal Medicine Team here at the RVC. There has been a couple of new drugs on the market one in the USA (bexagliflozin) and one in the UK (velagliflozin) both SGLT-2 inhibitors, oral hypoglycaemic agents to be used in newly diagnosed diabetic cats. We thought we’d chat to Chris about the information that is out there about these agents, how they can be used and what questions we have about their use. He recently spoke to our ECC team about euglycaemic diabetic ketoacidosis (eDKA) and I was intrigued. We hope that you enjoy. Some references: https://pubmed.ncbi.nlm.nih.gov/37148170/ https://pubmed.ncbi.nlm.nih.gov/34975223/ There is an abstract on page 2512 here https://onlinelibrary.wiley.com/doi/10.1111/jvim.16559 To Cite this podcast as: Dom Barfield. RVC Clinical Podcast 140 Oral hypoglycaemic drugs for diabetic cats with Chris Scudder. Published on Dec 15 2023 If you have any comments about this podcast, please get in touch: email [email protected] or follow us on instagram @rvcclinicalpodcast. We would greatly appreciate your time to rate us on Apple podcast, podbean or Acast and kindly write us a review.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related